From Towa
to the World

Our Journey begins in 1951

Towa Pharmaceutical was founded in Osaka, Japan as a wholesale and brokerage of pharmaceutical raw materials.

Towa Group contributes to people’s health by creating superior products and services.

Through our corporate activities, we aim to be a company that is valued and needed by patients, medical professionals, local communities, and others.

In 2020 Towa became international by adding the Pensa Pharma business, a well-established patent medicine platform with a commercial presence in the US and the EU and R&D and manufacturing capabilities.

Through this internationalization milestone, Towa International headquarters were established in Barcelona, Spain.

At Towa International, we work to research, develop and market generic and value-added medicines (VAM) that contribute to improving the health of patients. In turn, they allow greater availability and better management of treatments for health professionals and support the sustainability of health systems in more than 30 countries in which we operate.

#FromTowaToTheWorld

Our story together

TOWA
PHARMACEUTICAL

TOWA
INTERNATIONAL

1951

Towa Pharmaceutical was founded.

1989

Pensa originates from PPI expertise and a non-infringement formulation of Omeprazole

1992

Contruction of Martorelles (Barcelona) manufacturing and R&D facilities

1996

Mr. Itsuro Yoshida became the president

1998

Creation of B2B business 

1998

Osaka Research Center and Osaka Distribution Center are constructed at Ichiban-cho, Kadoma, Osaka

1999

Launch of Omeprazole 

2004

Towa was listed on stock exchange 

2006

Pensa Pharma Foundation

2007

Start of the internationalisation phaseExpanded Pensa into Italy with the purchase of 20 additional products. 

2008

Built pilot plant and expanded R&D capabilities. Entered Portugal through the acquisition of toLife, adding 30 additional products to Pensa’s portfolio 

2009

Entered U.S.A with acquisition of Breckenridge. Entered Sweeden 

2010

Towa purchases Daichi Kasei Co., Ltd., and makes it subsidiary 

2012

Entered Germany 

2016

Established Greencaps Pharmaceutical Co., Ltd.

2020

Foundation of Towa Pharma International Holding

2020

Internationalisation

2021

Expansion manufacturing facilities 

2021

Towa purchases Protosera Inc. and makes it subsidiary  

2022

Internalization process. Entering South America and Middle East though licenses 

2022

Towa purchases Sunsho Pharmaceutical Co., Ltd. and makes it subsidiary